DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy

The purpose of this study was to evaluate the importance of diffusion-weighted magnetic resonance imaging (DW-MRI) apparent diffusion coefficient (ADC) values to predict treatment response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC). Thirty-two patients with LABC underwent 2–4 cylces of NCT (docetaxel and epirubicin). The DW-MRI scans were performed within one week prior to chemotherapy and after the first course of treatment, respectively. Accordingly, tumor volumes, changes in tumor ADC values, and their degree of correlation were analyzed. The overall response (OR) was observed in 62.5% (95% CI, 45.7–79.3%) of patients after 2 cycles of NCT. The clinical complete response (CR) rate and pathological CR (pCR) rate were 15.6 and 9.4%, respectively. The stable disease (SD) rate was 34.4% (11 patients), and progressive disease (PD) was observed in only one patient (3.1%). After the first cycle of NCT, the ADC values in the CR + PR group significantly increased (P < 0.001). The initial ADC values before chemotherapy in the OR group were significantly lower than those in the SD + PD group (P < 0.001). The initial ADC values and the changes in tumor volume after chemotherapy were negatively correlated (r = −0.58, P = 0.02). The lower the initial tumor ADC value was the more obvious the decrease in tumor volume after chemotherapy. The changes in ADC values of tumors after chemotherapy and the changes in tumor volume were positively correlated (r = 0.96, P < 0.001). After chemotherapy, the greater the change in ADC value, the more the tumor volume was reduced. Using the initial ADC values of breast cancer tumors and the early changes in ADC values after NCT, we may be able to predict tumor response to chemotherapy. Tumors with low initial ADC values may be sensitive to chemotherapy; tumors with significantly increasing ADC values early after chemotherapy may be sensitive to chemotherapy.

[1]  J. Hogg.  Magnetic resonance imaging. , 1994, Journal of the Royal Naval Medical Service.

[2]  James M Provenzale,et al.  Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. , 2002, Radiology.

[3]  D. Le Bihan,et al.  Diffusion tensor imaging: Concepts and applications , 2001, Journal of magnetic resonance imaging : JMRI.

[4]  T. Hirai,et al.  Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results , 2006, European Radiology.

[5]  D. Collins,et al.  Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.

[6]  Elkan F Halpern,et al.  Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. , 2003, Radiology.

[7]  R. Gillies,et al.  Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. , 2004, Neoplasia.

[8]  K. Zou,et al.  Multi‐component apparent diffusion coefficients in human brain: Relationship to spin‐lattice relaxation , 2000, Magnetic resonance in medicine.

[9]  Stephan E Maier,et al.  Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. , 2004, Neoplasia.

[10]  U. Sharma,et al.  Longitudinal study of the assessment by MRI and diffusion‐weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy , 2009, NMR in biomedicine.

[11]  Dianne Georgian-Smith,et al.  Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.

[12]  Peter Gibbs,et al.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.

[13]  S E Harms,et al.  Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging , 1996, Cancer.

[14]  T. Chenevert,et al.  Anisotropic diffusion in human white matter: demonstration with MR techniques in vivo. , 1990, Radiology.

[15]  L. Turnbull,et al.  Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy , 2006, British Journal of Cancer.

[16]  J. Ahn,et al.  Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer , 2008, Cancer Chemotherapy and Pharmacology.

[17]  J. Gore,et al.  Theoretical Model for Water Diffusion in Tissues , 1995, Magnetic resonance in medicine.

[18]  Masahiko Watanabe,et al.  Diffusion-Weighted Imaging of Malignant Breast Tumors: The Usefulness of Apparent Diffusion Coefficient (ADC) Value and ADC Map for the Detection of Malignant Breast Tumors and Evaluation of Cancer Extension , 2005, Journal of computer assisted tomography.

[19]  P. Hüppi,et al.  Diffusion tensor imaging of normal and injured developing human brain ‐ a technical review , 2002, NMR in biomedicine.

[20]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Basser,et al.  Estimation of the effective self-diffusion tensor from the NMR spin echo. , 1994, Journal of magnetic resonance. Series B.

[22]  C. Meyer,et al.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Maier,et al.  High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. , 2004, Radiology.

[24]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Zuiani,et al.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy , 2004, European Radiology.

[27]  K. Camphausen,et al.  Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer , 2010, Breast Cancer Research and Treatment.

[28]  D. Norris,et al.  Healthy and infarcted brain tissues studied at short diffusion times: The origins of apparent restriction and the reduction in apparent diffusion coefficient , 1994, NMR in biomedicine.

[29]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[30]  T L Chenevert,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.